(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
30 January 2020 (30.01.2020)

WIPO | PCT

(10) International Publication Number
WO 2020/020751 A1

(51) International Patent Classification:
*A61K 31/5415* (2006.01) *A61P 25/28* (2006.01)
*A61K 45/06* (2006.01)

(21) International Application Number:
PCT/EP2019/069428

(22) International Filing Date:
18 July 2019 (18.07.2019)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

| | | |
|---|---|---|
| 1812193.9 | 26 July 2018 (26.07.2018) | GB |
| 1909458.0 | 01 July 2019 (01.07.2019) | GB |


(71) Applicant: **WISTA LABORATORIES LTD.** [SG/SG]; 25 Bukit Batok Crescent, The Elitist #06-13, Singapore 658066 (SG).

(71) Applicant *(for MG only)*: **HARRINGTON, Charles Robert** [GB/GB]; c/o TauRx Therapeutics Ltd., 395 King Street, Aberdeen Aberdeenshire AB24 5RP (GB).

(72) Inventors: **WISCHIK, Claude Michel**; c/o TauRx Therapeutics Ltd., 395 King Street, Aberdeen Aberdeenshire AB24 5RP (GB). **SCHELTER, Björn Olaf**; c/o TauRx Therapeutics Ltd., 395 King Street, Aberdeen Aberdeenshire AB24 5RP (GB). **SHIELLS, Helen Christine**; c/o TauRx Therapeutics Ltd., 395 King Street, Aberdeen Aberdeenshire AB24 5RP (GB).

(74) Agent: **MEWBURN ELLIS LLP**; City Tower, 40 Basinghall Street, London Greater London EC2V 5DE (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**
— *of inventorship (Rule 4.17(iv))*

**Published:**
— *with international search report (Art. 21(3))*

WO 2020/020751 A1

(54) Title: OPTIMISED DOSAGE OF DIAMINOPHENOTHIAZINES IN POPULATIONS

(57) Abstract: The invention provides novel dosing regimens for Leuco-Methylthioninium (LMT) compounds which maximise the proportion of subjects in which the MT concentration will exceed concentrations in which therapeutic efficacy in relation to treatment of neurodegenerative disorders such as Alzheimer's disease and rontotemporal dementias can be achieved, while maintaining a desirable clinical profile. Also provided are LMT- containing dosage units and other compositions.